Skip to main content

Connective Tissue Diseases clinical trials at UC Davis

2 research studies open to eligible people

Showing trials for
  • A Study of Experimental Ralinepag for Pulmonary Arterial Hypertension (PAH)

    open to eligible people ages 18-75

    Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

    Sacramento, California and other locations

  • A Study of Experimental Ralinepag in Pulmonary Arterial Hypertension

    open to eligible people ages 18-75

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

    Sacramento, California and other locations

Last updated: